company background image
XLY

Auxly Cannabis Group TSX:XLY Stock Report

Last Price

CA$0.08

Market Cap

CA$72.6m

7D

6.7%

1Y

-65.2%

Updated

09 Aug, 2022

Data

Company Financials +
XLY fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

XLY Stock Overview

Auxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada.

Auxly Cannabis Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Auxly Cannabis Group
Historical stock prices
Current Share PriceCA$0.08
52 Week HighCA$0.35
52 Week LowCA$0.065
Beta0.89
1 Month Change14.29%
3 Month Change-48.39%
1 Year Change-65.22%
3 Year Change-91.58%
5 Year Change-89.33%
Change since IPO-85.46%

Recent News & Updates

Jul 21
Health Check: How Prudently Does Auxly Cannabis Group (TSE:XLY) Use Debt?

Health Check: How Prudently Does Auxly Cannabis Group (TSE:XLY) Use Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Shareholder Returns

XLYCA PharmaceuticalsCA Market
7D6.7%0.04%0.3%
1Y-65.2%-66.8%-2.0%

Return vs Industry: XLY exceeded the Canadian Pharmaceuticals industry which returned -66.3% over the past year.

Return vs Market: XLY underperformed the Canadian Market which returned -1.2% over the past year.

Price Volatility

Is XLY's price volatile compared to industry and market?
XLY volatility
XLY Average Weekly Movement15.8%
Pharmaceuticals Industry Average Movement13.4%
Market Average Movement10.8%
10% most volatile stocks in CA Market19.4%
10% least volatile stocks in CA Market4.3%

Stable Share Price: XLY is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: XLY's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
1987558Hugo Alveshttps://auxly.com

Auxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada. The company focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. It offers cannabis products under various forms, including vape catridges, dried flower, concentrates, chocolates, soft chews, oil drops, capsules, topicals, and hard candy under the brands KOLAB PROJECT, Dosecann, BACK FORTY, and Foray.

Auxly Cannabis Group Fundamentals Summary

How do Auxly Cannabis Group's earnings and revenue compare to its market cap?
XLY fundamental statistics
Market CapCA$72.56m
Earnings (TTM)-CA$75.42m
Revenue (TTM)CA$97.29m

0.7x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XLY income statement (TTM)
RevenueCA$97.29m
Cost of RevenueCA$76.67m
Gross ProfitCA$20.62m
Other ExpensesCA$96.04m
Earnings-CA$75.42m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 15, 2022

Earnings per share (EPS)-0.083
Gross Margin21.19%
Net Profit Margin-77.53%
Debt/Equity Ratio101.1%

How did XLY perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is XLY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XLY?

Other financial metrics that can be useful for relative valuation.

XLY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.5x
Enterprise Value/EBITDA-7.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does XLY's PS Ratio compare to its peers?

XLY PS Ratio vs Peers
The above table shows the PS ratio for XLY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average7.8x
NUMI Numinus Wellness
26x152.7%CA$73.0m
RWB Red White & Bloom Brands
1.3xn/aCA$71.0m
IMCC IM Cannabis
0.6x22.8%CA$41.8m
LOVE Cannara Biotech
3xn/aCA$92.1m
XLY Auxly Cannabis Group
0.7x28.7%CA$72.6m

Price-To-Sales vs Peers: XLY is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (7.8x).


Price to Earnings Ratio vs Industry

How does XLY's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?

Price-To-Sales vs Industry: XLY is good value based on its Price-To-Sales Ratio (0.7x) compared to the Canadian Pharmaceuticals industry average (1.7x)


Price to Sales Ratio vs Fair Ratio

What is XLY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XLY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.7x
Fair PS Ratio2.2x

Price-To-Sales vs Fair Ratio: XLY is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).


Share Price vs Fair Value

What is the Fair Price of XLY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: XLY (CA$0.08) is trading below our estimate of fair value (CA$3.3)

Significantly Below Fair Value: XLY is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Auxly Cannabis Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


51.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XLY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XLY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XLY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XLY's revenue (28.7% per year) is forecast to grow faster than the Canadian market (6.3% per year).

High Growth Revenue: XLY's revenue (28.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XLY's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Auxly Cannabis Group performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-24.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: XLY is currently unprofitable.

Growing Profit Margin: XLY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XLY is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.

Accelerating Growth: Unable to compare XLY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XLY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (72.5%).


Return on Equity

High ROE: XLY has a negative Return on Equity (-43.44%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Auxly Cannabis Group's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: XLY's short term assets (CA$125.2M) exceed its short term liabilities (CA$51.4M).

Long Term Liabilities: XLY's short term assets (CA$125.2M) do not cover its long term liabilities (CA$192.4M).


Debt to Equity History and Analysis

Debt Level: XLY's net debt to equity ratio (91.6%) is considered high.

Reducing Debt: XLY's debt to equity ratio has increased from 14.7% to 101.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XLY has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: XLY has less than a year of cash runway if free cash flow continues to reduce at historical rates of 28.7% each year


Discover healthy companies

Dividend

What is Auxly Cannabis Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate XLY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XLY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XLY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XLY's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as XLY has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Hugo Alves (50 yo)

3yrs

Tenure

CA$2,838,000

Compensation

Mr. Hugo M. Alves serves as Chief Executive Officer of Auxly Cannabis Group Inc. since August 27, 2019 and is a Co-Founder of Auxly Cannabis Group. Mr. Alves served as Director at BC Craft Supply Co. Ltd....


CEO Compensation Analysis

Compensation vs Market: Hugo's total compensation ($USD2.20M) is above average for companies of similar size in the Canadian market ($USD186.89K).

Compensation vs Earnings: Hugo's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: XLY's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: XLY's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.4%.


Top Shareholders

Company Information

Auxly Cannabis Group Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Auxly Cannabis Group Inc.
  • Ticker: XLY
  • Exchange: TSX
  • Founded: 1987
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$72.556m
  • Shares outstanding: 906.94m
  • Website: https://auxly.com

Number of Employees


Location

  • Auxly Cannabis Group Inc.
  • 777 Richmond Street West
  • Unit 002
  • Toronto
  • Ontario
  • M6J 0C2
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/09 00:00
End of Day Share Price2022/08/09 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.